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Abstract 
Previous research has demonstrated that sleep disturbances show little improvement with evidence-
based psychotherapy for posttraumatic stress disorder (PTSD); however, sleep improvements are 
associated with PTSD treatment outcomes. The goal of the current study was to evaluate changes in 
self-reported insomnia symptoms and the association between insomnia symptoms and treatment 
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outcome during a 3-week intensive treatment program (ITP) for veterans with PTSD that integrated 
cognitive processing therapy (CPT), mindfulness, yoga, and other ancillary services. As part of 
standard clinical procedures, veterans (N = 165) completed self-report assessments of insomnia 
symptoms at pre- and posttreatment as well as self-report assessments of PTSD and depression 
symptoms approximately every other day during treatment. Most veterans reported at least moderate 
difficulties with insomnia at both pretreatment (83.0%–95.1%) and posttreatment (69.1–71.3%). 
Statistically significant reductions in self-reported insomnia severity occurred from pretreatment to 
posttreatment; however, the effect size was small, d = 0.33. Longitudinal mixed-effects models 
showed a significant interactive effect of Changes in Insomnia x Time in predicting PTSD and 
depression symptoms, indicating that patients with more improvements in insomnia had more positive 
treatment outcomes. These findings suggest that many veterans continued to struggle with sleep 
disruption after a 3-week ITP, and successful efforts to improve sleep could lead to better PTSD 
treatment outcomes. Further research is needed to establish how adjunctive sleep interventions can be 
used to maximize both sleep and PTSD outcomes.  
Sleep disturbance is rated as one of the most pressing concerns among veterans with 
posttraumatic stress disorder (PTSD; Rosen, Adler, & Tiet, 2013) and has been independently 
associated with higher suicide risk (Ribeiro et al., 2012) and poorer physical health (Clum, Nishith, & 
Resick, 2001). However, evidence suggests that sleep disturbance is refractory to front-line evidence-
based psychotherapies for PTSD and that sleep symptoms persist even with significant PTSD 
symptom improvement (e.g., Belleville, Guay, & Marchand, 2009; Galovski, Monson, Bruce, & 
Resick, 2009; Gutner, Casement, Gilbert, & Resick, 2013; Pruiksma et al., 2016). For example, 
Pruiksma and colleagues (2016) found that among U.S. Army soldiers who no longer met the criteria 
for PTSD following treatment, 57% continued to report problems with insomnia. 
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In addition to causing significant distress, sleep disturbance may negatively impact treatment 
outcomes for PTSD. Sleep has been shown to be important for memory and learning processes 
(Diekelmann & Born, 2010) that are thought to be crucial for effective cognitive behavioral 
treatments for PTSD. In several studies, poorer baseline sleep quality was not shown to reduce the 
overall effectiveness of prolonged exposure therapy (López, Lancaster, Gros, & Acierno, 2017; 
Sexton et al., 2017) or cognitive therapy for PTSD (Lommen et al., 2016). However, López and 
colleagues (2017) showed that residual sleep symptoms, calculated by predicting posttreatment scores 
from baseline scores, predicted poorer treatment outcomes. Additionally, Lommen and colleagues 
(2016) revealed a bidirectional association between changes in insomnia and changes in PTSD. These 
findings suggest that improvements in sleep quality during treatment may help to improve PTSD 
treatment outcomes and that adjunctive interventions may be needed to improve sleep in the context 
of PTSD to maximize both sleep and PTSD outcomes. Given evidence that although pretreatment 
sleep disturbance does not impact PTSD treatment outcomes, changes in sleep disturbance during 
treatment are predictive of treatment outcome, it may be that PTSD treatment and adjunctive sleep 
interventions need to be delivered simultaneously to be most effective.  
Intensive PTSD treatments are increasingly being used to overcome traditional treatment 
barriers and offer the opportunity for clinicians to deliver multiple treatment modalities 
simultaneously (Beidel, Frueh, Neer, & Lejuez, 2017; Harvey et al., 2017). We recently demonstrated 
that a 3-week daily intensive treatment program (ITP) that delivered cognitive processing therapy 
(CPT), mindfulness, yoga, and other services led to large reductions in PTSD and depression 
symptoms among veterans with PTSD (Zalta et al., 2018). There is some evidence to suggest that 
integrative treatments, such as mindfulness and yoga, which are frequently offered in ITPs (Harvey et 
al., 2017), may lead to sleep improvements among veterans (McCarthy et al., 2017; Nakamura, 
Lipschitz, Landward, Kuhn, & West, 2011; Staples, Hamilton, & Uddo, 2013). Thus, we sought to 
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examine (a) the degree to which self-reported insomnia symptoms improved over the course of the 
ITP, (b) whether baseline insomnia symptoms predicted changes in PTSD and depression severity, 
and (c) whether changes in self-reported insomnia symptoms predicted changes in PTSD and 
depression severity. Although we were unable to evaluate objective sleep measures and comorbid 
sleep conditions in the context of this effectiveness study, this study represents an important step in 
understanding the role of insomnia symptoms in intensive PTSD treatment.   
Method 
Participants and Procedure 
 The sample consisted of 165 U.S. veterans and service members (henceforth collectively 
referred to as “veterans”) who completed a 3-week, cohort-based ITP at a mental health clinic that 
was not part of the Veterans Affairs (VA) health care system, between April 2016 and November 
2017. Of note, the ITP program is still offered as of the writing of this paper. The study sample was 
limited to this date range because insomnia-related measures were not administered after this time. 
For cohorts that were treated during this time period, the median cohort size was 10 (range: 5–14). 
Veterans come from across the U.S. to attend the program, which is provided at no cost and includes 
nearby accommodation for the duration of the ITP. For participants in the present study, as for all 
program participants, accommodations included a private room in which veterans slept on their own, 
with the exception that spouses or other family members who chose to attend the program may have 
shared the veteran’s room in Week 3. Veterans were asked to check in to the treatment location by 
7:45 a.m. on weekdays for the intervention program; there was no set bedtime or sleep schedule on 
weekends. 
Characteristics of the sample are reported in Table 1. Based on information from the 
American Community Survey Public Use Microdata Sample (U.S. Department of Veterans Affairs, 
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2016), the demographic characteristics of our sample were similar to those for the general population 
of veterans who served following the September 11, 2001 (9/11), terror attacks, except that there was 
a larger percentage of female veterans in our sample. All veterans reported a history of military 
trauma and met diagnostic criteria for PTSD based on the Clinician-Administered PTSD Scale 
(CAPS) for the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; 
Weathers et al., 2018). All study procedures were approved by the institutional review board at Rush 
University Medical Center, with a waiver of consent, as all assessments were collected as part of 
routine clinical care. 
All veterans in the present sample completed a 3-week, cohort-based ITP (see Zalta et al., 
2018 for a detailed description). The program offered two treatment tracks: one for combat-based 
PTSD and one for military sexual trauma (MST)–based PTSD. The primary treatment components 
included 14 sessions of individual CPT (Resick, Monson, & Chard, 2016); 13 sessions of group CPT; 
13 sessions of group mindfulness, adapted from the mindfulness-based stress reduction program 
(Kabat-Zinn, 1990); and 12 sessions of yoga. In addition to these core components, veterans received 
several secondary interventions, including psychoeducation, nutrition and fitness, art therapy, case 
management, medication management (optional), and acupuncture (optional). One of the 1-hour 
psychoeducation sessions in Week 1 focused on sleep hygiene and included information and 
education on maintaining a regular sleep schedule, avoiding naps and substances that interfere with 
sleep, creating an environment to support sleep, stimulus control principles, and strategies to manage 
worry. Previous research with an overlapping sample of veterans showed that this treatment resulted 
in large pre- to posttreatment symptom reductions in PTSD and depression, ds = 1.04–1.41 (Zalta et 
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Measures 
 Sample characteristics. Prior to the start of treatment, demographic and military 
characteristics were collected for all veterans; information collected included age; sex; race; ethnicity; 
deployment history, coded as number of deployments and location of deployments;  service era, 
coded dichotomously as pre- or post-9/11; military service status, coded dichotomously as 
discharged/retired versus active duty/National Guard/reserves/inactive ready reserve; and branch of 
service. Participants’ history of childhood trauma and combat exposure were assessed using an 
author-developed trauma history questionnaire (see Held, Boley, Karnik, Pollack, & Zalta, 2018 for 
details), which asked participants to respond to items about exposure to 21 types of traumatic events 
and, if they endorsed an item, to indicate whether the trauma occurred in childhood, adulthood, or 
both. 
Self-reported insomnia symptoms. Participants completed the Insomnia Severity Index (ISI; 
Bastien, Vallières, & Morin, 2001) at pre- and posttreatment. The ISI is a 7-item measure that is used 
to assess symptoms of insomnia over the preceding 2 weeks. Responses are summed and categorized 
as no clinically significant insomnia (score of 0–7), subthreshold insomnia (score of 8–14), moderate 
clinical insomnia (score of 15–21), or severe clinical insomnia (score of 22–28; Morin, 1993). In the 
present sample, the Cronbach’s alpha values for internal consistency for the ISI were .82 at 
pretreatment and .90 at posttreatment.  
PTSD symptoms. Symptoms of PTSD were assessed at pretreatment, posttreatment, and 
approximately every other day during the course of treatment (i.e., a total of ten assessments over the 
19-day treatment period). Past-week PTSD symptoms were assessed using the 20-item PTSD 
Checklist for DSM-5 (PCL-5; Weathers et al., 2013). The PCL-5 asks respondents to rate the degree 
to which they have been bothered by each PTSD symptom on a 5-point Likert-type scale that ranges 
from 0 (not at all) to 4 (extremely). In order to avoid overlap in measuring the severity of sleep 
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problems, we calculated a modified 18-item total score (PCL-5-18) that excluded the two sleep-
related questions on the PCL-5 (Item 2: “repeated, disturbing dreams of the stressful experience” and 
Item 20: “trouble falling or staying asleep”). The PCL-5-18 exhibited strong internal consistency, with 
Cronbach’s alpha values of .88 at pretreatment and .96 at posttreatment.  
Depression symptoms. Depression symptoms were assessed at pre- and posttreatment as 
well as seven times during treatment (i.e., a total of nine assessments over the 19-day treatment 
period). The nine-item version of the Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer & 
Williams, 2001) was used to assess symptoms of depression over the past 2 weeks. We calculated a 
modified total score that excluded Item 3, which is related to sleep disturbances, thus creating an 
eight-item measure of depression that does not include sleep problems (PHQ-8). The PHQ-8 exhibited 
strong internal consistency at both pretreatment, Cronbach’s α = .81, and posttreatment, Cronbach’s α 
= .87. 
Data Analysis 
A paired t test was conducted to assess pre- to posttreatment change in ISI scores. Due to their 
utility in modeling individual change over time and data that are missing at random (for review see 
Hedeker & Gibbons, 2006), mixed-effects regression models were used to assess predictors of change 
in PHQ-8 and PCL-5-18 over time. All reported models included time, with a quadratic time 
component for PCL-5-18, and were adjusted for sex, age, presence of childhood trauma, and cohort 
type (MST or combat). We conducted iterations of these models that (a) adjusted for combat 
exposure, number of deployments, major depression diagnosis, substance use diagnosis, and use of 
sleep medications, and (b) examined only PCL-5-18 hyperarousal–related symptoms as the outcome. 
None of the covariates were related to either outcome, and the pattern of results was not influenced in 
any meaningful way based on the inclusion of these covariates or the change in outcome to the 
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hyperarousal-only items. Therefore, only models that adjusted for variables previously identified as 
relevant are reported here; the results of these supplemental analyses are available upon request. 
A small number of participants with missing covariate data were excluded from analyses 
when these analyses included relevant covariates (see Table 1 for relevant sample sizes). 
Conditionally independent errors were selected based on Akaike information criteria (AIC) values as 
well as random intercept and slope components, due to improved model fit in likelihood ratio tests, ps 
< .001. Due to a lack of emphasis on comparing covariate slopes, unstandardized coefficients are 
reported. The results were considered significant at p < .05. All analyses were conducted in Stata 
(Version 15), and figures were created in Sigmaplot (Version 13). 
The ISI captured ratings of insomnia symptoms that occurred during the past two weeks, 
which resulted in a large degree of overlap with the intervention period. Thus, we conducted a series 
of sensitivity analyses using PCL-5 Item 20 (“trouble falling or staying asleep”), for which 
participants used the past week as a reference for their rating. Specifically, we evaluated the degree to 
which changes in ISI scores were related to changes in scores on PCL-5 Item 20, the percentage of 
participants who reported at least moderate distress (score of 2–4) on the item at pre- and 
posttreatment, and the percentage of individuals with moderate distress at baseline who reported at 
least a 2-point improvement at endpoint. We also conducted the longitudinal mixed-effect regression 
models using PCL-5 Item 20 rather than ISI as a predictor. Of the 165 veterans in the sample, we were 
able to calculate a change score for the 143 who had a PCL-5 Item 20 score at pre- and posttreatment. 
Reasons for missing data on this variable included the fact that the past-week version of the PCL-5 
was not added to the program until June 2016, and some veterans left the program prior to completing 
assessments on the last day. For the PCL-5-18 and PHQ-8, the amount of missingness at each time 
point ranged from 1.21% (Day 5) to 10.91% (Day 14). The amount of missingness was not 
significantly related to any demographic or outcome variable of interest.  
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Results 
Most veterans reported moderate-to-severe insomnia symptoms, using an ISI score of 15 or 
higher as a cutoff (Bastien et al., 2001), at both pretreatment (83.0%) and posttreatment (69.1%). 
Statistically significant reductions in self-reported insomnia severity occurred from pretreatment (M = 
20.03, SD = 5.26) to posttreatment (M = 18.01, SD = 6.65), d = 0.33, p <.001.  However, only 21.2% 
of all veterans and 23.4% of treatment responders, who reported a minimum 10-point reduction on the 
PCL-5-18 during treatment, demonstrated a clinically meaningful improvement in self-reported 
insomnia symptoms from pre- to posttreatment, based on a reduction in ISI score of at least 6 points 
(Yang, Morin, Schaefer, & Wallenstein, 2009).  
The results of longitudinal mixed-effects regression models predicting PCL-5-18 and PHQ-8 
are presented in Table 2. These models indicated that baseline ISI scores predicted both overall PCL-
5-18 and PHQ-8 scores across all time points, ps < .001. However, Time x Baseline ISI Score 
interactions were not significant predictors of either the PCL-5-18, p = .123; or PHQ-8, p = .304, 
suggesting that outcome time trends did not differ based on baseline insomnia scores. Pre–post change 
in ISI score did not predict overall PCL-5-18 or PHQ-8 scores over time at the .05 level, ps = .159 and 
.084, respectively. However, Time x ISI Change interactions were significant for both the PCL-5-18, 
p < .001, and the PHQ-8, p =.002, suggesting that time trends in both outcomes differed based on the 
amount of ISI change during the program (see Figure 1 for the depiction of this interaction for PTSD 
symptoms). Participants who had a clinically meaningful improvement in ISI score (n = 35) had 
average posttreatment scores of 17.36 (SD = 16.17) on the PCL-5-18 and 6.66 (SD = 5.16) on the 
PHQ-8, whereas those who did not have a clinically meaningful improvement on the ISI (n = 130) 
had an average posttreatment score of 32.40 (SD = 15.82) on the PCL-5-18 and 10.98 (SD = 5.07) on 
the PHQ-8.  
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Change in ISI score from pre- to posttreatment was associated with reported change in PCL-5 
Item 20, r = .36, p < .001, suggesting moderate convergence between assessments of sleep 
difficulties. Of the participants with available data for PCL-5 Item 20 at baseline and endpoint (n = 
143), 136 (95.1%) reported at least moderate distress at baseline and 102 (71.3%) reported at least 
moderate distress at the endpoint. Of individuals who reported at least moderate distress at baseline (n 
= 136), 35 (25.7%) reported an improvement of at least 2 points on PCL-5 Item 20 at the endpoint 
assessment. The longitudinal mixed-effect regression models using PCL-5 Item 20 indicated a similar 
Time x Sleep Change interaction for both the PCL-5-18, B = -0.53, p < .001; and PHQ-8, B = -0.14, p 
< .001, outcomes (see Supplemental Table 1). 
Discussion 
We have previously shown that our 3-week intensive outpatient program for veterans with 
PTSD leads to large and clinically meaningful changes in PTSD and depression symptoms (Zalta et 
al., 2018). However, the current results reveal that, despite these improvements, most veterans 
continue to report at least moderate sleep difficulties at posttreatment and few appear to have 
clinically meaningful improvements in insomnia symptoms during treatment. Our findings are similar 
to those reported in previous PTSD treatment studies (e.g., Belleville et al., 2009; Pruiksma et al., 
2016). By contrast, research has shown that sleep-specific cognitive behavioral treatments lead to 
large reductions in insomnia among individuals with PTSD (Ho, Chan, & Tang, 2016). These findings 
suggest that to effectively target sleep among individuals with PTSD, adjunctive treatments may need 
to be sleep-specific rather than broad (e.g., mindfulness and yoga). Our ITP treatment included a 1-
hour psychoeducational group on sleep hygiene; however, this appeared to be insufficient for making 
a meaningful impact on self-reported insomnia symptoms. Recent pilot data suggest that integrating 
aspects of established sleep interventions, such as cognitive behavioral therapy for insomnia (Morin, 
2006), with PTSD treatments may be a promising approach (Colvonen, Drummond, Angkaw, & 
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Norman, 2019). Further research is needed to determine the timing and dose needed to maximize both 
sleep and PTSD outcomes. 
Consistent with previous research, our findings show that self-reported insomnia severity at 
baseline did not predict changes in PTSD and depression severity across time. However, larger 
improvements in ratings of insomnia symptoms were associated with better PTSD and depression 
outcomes. Notably, a PCL-5 score of 33 or higher is considered to be indicative of probable PTSD, 
which can be extrapolated to a score of 29.7 for the 18-item version used in the current study; 
individuals who had a clinically meaningful change in ISI score were well below this cutoff at 
treatment completion, whereas those who did not have a clinically meaningful change in ISI score 
were above the extrapolated cutoff at treatment completion. These findings suggest that having more 
severe insomnia prior to treatment does not diminish the likelihood of successful PTSD treatment 
although the improvement of insomnia during PTSD treatment does improve the likelihood of 
treatment success. One possible explanation for these findings is that sleep disturbances may be 
etiologically linked to PTSD symptoms for some individuals, and for these individuals, sleep 
disturbances respond to PTSD treatments. For others, the pathophysiology of sleep disturbances may 
be independent of PTSD; this comorbidity may require adjunctive interventions to address sleep 
problems and may make individuals more refractory to PTSD treatments. More research is needed to 
understand the underlying processes that contribute to co-occurring PTSD and sleep disturbance and 
help determine which individuals with PTSD would benefit from adjunctive sleep treatments. 
One of the key limitations of our approach was that the ISI assessed insomnia symptoms that 
occurred over the past two weeks. Thus, the posttreatment assessment (i.e., end of Week 3) included a 
significant portion of the treatment period and may not have fully captured improvements in insomnia 
that occurred during treatment. To address this issue, we conducted sensitivity analyses using PCL-5 
Item 20, which assesses past-week sleep disturbance. Overall, these sensitivity analyses showed a 
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similar pattern of results with respect to the proportion of the sample who reported at least moderate 
distress at each timepoint and statistical significance of the interaction terms of interest. Thus, the 
sensitivity analyses increased confidence in our results with the ISI. However, a longer-term follow-
up will be important to determine whether insomnia symptoms continued to improve or rebounded 
with more time and a return to the home environment after treatment termination.   
Several additional limitations should be considered when interpreting our findings. We did 
not assess comorbid sleep disorders, such as sleep apnea, or changes in sleep medications over the 
course of the treatment; these factors may have an important impact on the degree to which insomnia 
changed over the course of treatment. We also did not examine our combined intensive treatment 
relative to a comparator group. Therefore, we cannot determine the degree to which changes in self-
reported insomnia symptoms were due to the intervention versus the passage of time. Moreover, we 
cannot determine whether the addition of mindfulness, yoga, and other ancillary services had an 
impact on insomnia symptoms. For example, it is possible that the intensive delivery of trauma 
treatment may temporarily worsen insomnia symptoms and that the addition of mindfulness and yoga 
may have mitigated this. It is also possible that the intensive delivery of mindfulness and yoga over 
the short, 3-week duration had a diminished impact on sleep and that adjunctive delivery of these 
services in more traditional outpatient care would have larger benefits. Finally, it is also possible that 
insomnia symptoms were affected by the fact that veterans were sleeping in a dormitory facility and 
not in their natural environment. 
Despite these limitations, our findings suggest that the simultaneous delivery of trauma-
focused treatment, mindfulness, and yoga in an intensive treatment format did not have a meaningful 
impact on self-reported insomnia symptoms among veterans with PTSD, yet improvement in self-
reported insomnia symptoms was linked to PTSD treatment outcomes. Addressing sleep concerns is 
important to patients with PTSD (Rosen et al., 2013) and is likely critical for the long-term well-being 
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of veterans. More frequent sleep assessments during the course of trauma-focused PTSD treatment 
may be warranted to determine who may benefit from adjunctive services. Further research is needed 
to explore how to best address co-occurring PTSD and sleep disturbance and maximize symptom 
improvement.    
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Variable n % N M SD Range 
Sex       
     Male 106  64.2     
     Female 59  35.8     
Cohort type       
     Combat cohort 112  67.9     
     MST cohort 53  32.1     
Race/ethnicity       
     Non-Hispanic White 94  57.0     
     Black or African American 32  19.4     
     Hispanic or Latino
a
 19  11.5     
     American Indian or Alaska Native 4  2.4     
     Asian 1  0.6     
     Native Hawaiian or other Pacific Islander 2  1.2     
     Other 13  7.9     
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Served after September 11, 2001       
     Yes 145  87.9     
     No 20 12.1     
Discharged/retired       
     Yes 151  91.5     
     No 14 8.5     
Service branch       
     Army/Army Reserve/Army National Guard 110  66.7     
     Air Force/Air Force Reserve/Air National Guard 15  9.1     
     Marines 23  13.9     
     Navy 16  9.7     
     Coast Guard 1  0.6     
History of childhood trauma        
     Yes 101  61.6     
     No 63 38.4     
Combat exposure       
     Yes 140  86.4     
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     No 22 13.6     
Age (years)   165 40.81 9.57 24–67 
Number of deployments    154 1.47  1.25 0–6 
Pretreatment PCL-5 total score    151 55.97  11.67 22–80 
Pretreatment PHQ-9 total score   165 17.72  4.93 6–27 
Note. MST = military sexual trauma; PCL = Posttraumatic Stress Disorder Checklist; PHQ = Patient 
Health Questionnaire. 
a
This category represents individuals with Hispanic or Latino ethnicity and 
White race. Individuals with Hispanic or Latino ethnicity who designated a non-White race were 
included in the designated race category.  
Table 2 
Longitudinal Random Effects Models of Insomnia Severity Index (ISI) Scores Predicting 
Posttraumatic Stress Disorder (PTSD) and Depression Symptoms During Treatment 
Variable PCL-5-18
a
   PHQ-8
b
   
 B SE B SE 
Time -0.47  0.49 -0.59* 0.15 
Time
2
 -0.10* 0.02 - 
Sex (male = 0) 1.25  1.87 0.13  0.88 
Childhood trauma (no = 0) -3.18* 1.32 -0.30  0.62 
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Cohort type (MST = 0) -2.64  1.94 -2.10* 0.91 
Age  0.01 0.07 -0.02  0.03 
Baseline ISI 0.91* 0.15 0.26* 0.08 
ISI pre–post change -0.20  0.14 -0.13  0.08 
Baseline ISI x Time  0.03  0.02 0.01  0.01 
ISI Pre–Post Change x 
Time  
-0.08* 0.02 -0.02* 0.01 
Note. N = 164. PCL = PTSD Checklist; PHQ = Patient Health Questionnaire.  
a
18-item version, which excluded items related to sleep. 
b
Eight-item version, which excluded one item 
related to sleep. The quadratic time component was not significant in models of PHQ-8 and was thus 
excluded from final PHQ-8 models. 
*p < .05. 
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Figure 1. Interaction between change in insomnia symptoms and time predicting posttraumatic stress 
disorder (PTSD) symptoms during treatment. High and low Insomnia Severity Index (ISI) change 
groups were based on +/- 1 standard deviation from the mean of ISI change from pre- to 
posttreatment. The error bars represent standard error. The Posttraumatic Stress Disorder Checklist for 
DSM-5 (PCL-5-18) comprised 18 items and excluded items related to sleep.  
